111 related articles for article (PubMed ID: 18640261)
1. Biotransformation of genistein and bisphenol A in cell lines used for screening endocrine disruptors.
Bursztyka J; Perdu E; Pettersson K; Pongratz I; Fernández-Cabrera M; Olea N; Debrauwer L; Zalko D; Cravedi JP
Toxicol In Vitro; 2008 Sep; 22(6):1595-604. PubMed ID: 18640261
[TBL] [Abstract][Full Text] [Related]
2. Use of external metabolizing systems when testing for endocrine disruption in the T-screen assay.
Taxvig C; Olesen PT; Nellemann C
Toxicol Appl Pharmacol; 2011 Feb; 250(3):263-9. PubMed ID: 21075132
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of the endocrine disruptor BPA by Xenopus laevis tadpoles.
Fini JB; Dolo L; Cravedi JP; Demeneix B; Zalko D
Ann N Y Acad Sci; 2009 Apr; 1163():394-7. PubMed ID: 19456369
[TBL] [Abstract][Full Text] [Related]
4. Effects of endocrine disruptors on genes associated with 17beta-estradiol metabolism and excretion.
Hanet N; Lancon A; Delmas D; Jannin B; Chagnon MC; Cherkaoui-Malki M; Latruffe N; Artur Y; Heydel JM
Steroids; 2008 Nov; 73(12):1242-51. PubMed ID: 18634814
[TBL] [Abstract][Full Text] [Related]
5. Computational modeling of serum-binding proteins and clearance in extrapolations across life stages and species for endocrine active compounds.
Teeguarden JG; Barton HA
Risk Anal; 2004 Jun; 24(3):751-70. PubMed ID: 15209943
[TBL] [Abstract][Full Text] [Related]
6. Weak estrogenic transcriptional activities of Bisphenol A and Bisphenol S.
Grignard E; Lapenna S; Bremer S
Toxicol In Vitro; 2012 Aug; 26(5):727-31. PubMed ID: 22507746
[TBL] [Abstract][Full Text] [Related]
7. Receptor binding characteristics of the endocrine disruptor bisphenol A for the human nuclear estrogen-related receptor gamma. Chief and corroborative hydrogen bonds of the bisphenol A phenol-hydroxyl group with Arg316 and Glu275 residues.
Liu X; Matsushima A; Okada H; Tokunaga T; Isozaki K; Shimohigashi Y
FEBS J; 2007 Dec; 274(24):6340-51. PubMed ID: 18005256
[TBL] [Abstract][Full Text] [Related]
8. A simple and extremely sensitive system for detecting estrogenic activity using transgenic Arabidopsis thaliana.
Tojo T; Tsuda K; Wada TS; Yamazaki K
Ecotoxicol Environ Saf; 2006 Jun; 64(2):106-14. PubMed ID: 16406577
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation of bisphenol A and its analogs (BPF, BPAF, BPZ and DMBPA) in human liver microsomes.
Schmidt J; Kotnik P; Trontelj J; Knez Ž; Mašič LP
Toxicol In Vitro; 2013 Jun; 27(4):1267-76. PubMed ID: 23470418
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific biotransformation of benzophenone-2 and bisphenol-s in zebrafish and human in vitro models used for toxicity and estrogenicity screening.
Le Fol V; Aït-Aïssa S; Cabaton N; Dolo L; Grimaldi M; Balaguer P; Perdu E; Debrauwer L; Brion F; Zalko D
Environ Sci Technol; 2015 Mar; 49(6):3860-8. PubMed ID: 25679259
[TBL] [Abstract][Full Text] [Related]
11. Development of a stable dual cell-line GFP expression system to study estrogenic endocrine disruptors.
Xu H; Kraus WL; Shuler ML
Biotechnol Bioeng; 2008 Dec; 101(6):1276-87. PubMed ID: 18980187
[TBL] [Abstract][Full Text] [Related]
12. Influence of metabolism on endocrine activities of bisphenol S.
Skledar DG; Schmidt J; Fic A; Klopčič I; Trontelj J; Dolenc MS; Finel M; Mašič LP
Chemosphere; 2016 Aug; 157():152-9. PubMed ID: 27213244
[TBL] [Abstract][Full Text] [Related]
13. Effect of bisphenol A with or without enzyme treatment on the proliferation and viability of MCF-7 cells.
Ricupito A; Del Pozzo G; Diano N; Grano V; Portaccio M; Marino M; Bolli A; Galluzzo P; Bontempo P; Mita L; Altucci L; Mita DG
Environ Int; 2009 Jan; 35(1):21-6. PubMed ID: 18640724
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of 2,3,3,3-tetrafluoropropene (HFO-1234yf).
Schuster P; Bertermann R; Snow TA; Han X; Rusch GM; Jepson GW; Dekant W
Toxicol Appl Pharmacol; 2008 Dec; 233(2):323-32. PubMed ID: 18817801
[TBL] [Abstract][Full Text] [Related]
15. Potential of various herbaceous species to remove the endocrine disruptor bisphenol A from aqueous media.
Loffredo E; Eliana Gattullo C; Traversa A; Senesi N
Chemosphere; 2010 Sep; 80(11):1274-80. PubMed ID: 20638099
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo phase II metabolism of combretastatin A-4: evidence for the formation of a sulphate conjugate metabolite.
Aprile S; Del Grosso E; Grosa G
Xenobiotica; 2009 Feb; 39(2):148-61. PubMed ID: 19255941
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a transgenic yeast screening system for estrogenicity and identification of the anti-estrogenic activity of malachite green.
Jiao B; Yeung EK; Chan CB; Cheng CH
J Cell Biochem; 2008 Dec; 105(6):1399-409. PubMed ID: 18980245
[TBL] [Abstract][Full Text] [Related]
18. OECD test strategies and methods for endocrine disruptors.
Gelbke HP; Kayser M; Poole A
Toxicology; 2004 Dec; 205(1-2):17-25. PubMed ID: 15458786
[TBL] [Abstract][Full Text] [Related]
19. Bisphenol A downregulates CYP19 transcription in JEG-3 cells.
Huang H; Leung LK
Toxicol Lett; 2009 Sep; 189(3):248-52. PubMed ID: 19539015
[TBL] [Abstract][Full Text] [Related]
20. Alternative methods in vitro for screening of endocrine disruptors.
Dvořáková M; Kejlová K; Bendová H; Rucki M; Kohout P; Vavrouš A; Jírová D
Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):123-131. PubMed ID: 28263540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
